The study was led by scientists at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center and the University of Vermont College of Medicine. The findings are published today (March 12, 2009) in the advance online edition of “Nature Genetics.”
Melanoma is a type of skin cancer that develops from pigment cells called melanocytes. It is the most rapidly increasing cancer in the United States, according to the National Cancer Institute, with more than 62,000 people diagnosed with the disease in 2008. Of these, it is estimated that more than 8,000 will die within three to four years after a form of the recurrent disease spreads, or metastasizes, to other sites in the body.
“There has not been a major advance in the treatment of metastatic melanoma in the last 25 years,” says Martin McMahon, PhD, senior co-author of the study and Efim Guzik Distinguished Professor in Cancer Biology at the UCSF. “While other cancers are more common, it is the rate of increase and the often aggressive course of the disease that worries people who study melanoma.”
By far the earliest and most common genetic alteration in melanoma is a mutation in an oncogene—a gene that can cause normal cells to become cancer cells—called BRAF. For this study, scientists generated a mouse that allowed them to switch on that oncogene in melanocytes. The research team found that the benign lesions observed in a mouse expressing the gene are very similar to the benign sun-induced moles that often develop in humans and which also contain BRAF mutations. Benign sun-induced moles generally never progress to malignancy, but such lesions are a potential precursor to cancer.
BRAF mutation is not the only genetic alteration observed in human melanoma. It is often found in combination with the silencing of PTEN, an important tumor-suppressor gene. By combining activation of the BRAF gene with deletion of the PTEN suppressor gene, the research team effectively modeled a combination of mutations seen in about 30 percent of all malignant melanomas. Under these circumstances the mice rapidly developed melanoma that displayed extensive metastasis.
Next, the researchers studied the impact of a combination of two different drugs on mouse melanoma. Each drug in its own unique way targeted the internal growth control circuits of cancer cells. One drug is an experimental therapy supplied by Pfizer Inc., that inhibits the action of a protein called MEK that acts “directly downstream of BRAF,” McMahon explained. Consequently, oncogenic BRAF gene generates a series of signals that support a high level of MEK activity. The other drug, Rapamycin, is an immunosuppressant drug already in clinical trials for cancer. As single agents, these drugs could prevent the onset of melanoma but, more importantly, when administered in combination to mice with pre-existing melanoma, there was a modest but statistically important level of regression in cancerous cells, according to McMahon.
“The study indicates that the mouse model we have built, based on the cardinal genetic features of the human disease, can be used to test responses to targeted therapeutics,” says McMahon. “The signal failure to improve the prognosis of metastatic melanoma patients is likely to be improved on in years to come by the use of agents that target specific genetic mutations in the disease. Nevertheless I believe it will up be three to five years before the types of pre-clinical experiments we are doing right now will result in improved prognosis for patients with metastatic melanoma.”
The scientists emphasized that although they engineered mice with very specific genetic alterations, it is possible that human melanoma is genetically more complex than the model they have generated. To address this, McMahon and Boris Bastian, MD, professor of dermatology and clinical professor of pathology at UCSF, are discussing the possibility of making additional modifications to the mouse model to make it more relevant to the genetic complexity found in human melanoma.
“Although the combination of drugs we administered might not be used in the clinic, our work suggests further avenues of research in a pre-clinical setting and in clinical trials,” says McMahon. “In fact it is fair to say also that there are a number of drugs already in clinical trials that target the same pathways we are interested in.”
The work was an integral collaboration between McMahon’s laboratory at UCSF and the laboratory of Marcus Bosenberg, MD, PhD at the University of Vermont. Bosenberg is a senior co-author with McMahon. The studies at the University of Vermont were primarily conducted by David P. Curley, a student in the laboratory of Bosenberg. The work at UCSF was primarily carried out by a post-doctoral fellow, David Dankort, PhD, who has since become a faculty member at McGill University in Montreal.
Additional co-authors of the paper were Robert A. Cartlidge and Anthony N. Kamezis of the UCSF Helen Diller Family Comprehensive Cancer Center, Betsy Nelson and William E. Damsky, Jr., of the University of Vermont College of Medicine, and Mingjian J. You and Ronald A. DePinho of the Dana-Farber Cancer Institute and Harvard Medical School.
The study was supported by the Diana Ashby Award of The Melanoma Research Foundation, which was presented to McMahon, a UC Discovery grant in partnership with Genentech, Inc., and the National Institutes of Health.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
Jennifer O’Brien | EurekAlert!
Closing the carbon loop
08.12.2016 | University of Pittsburgh
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences